Found 51 clinical trials
Arcadia: AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke
Objectives Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial
- 0 views
- 29 Nov, 2022
- 1 location
AnticoaguLation ONE Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation (ALONE AF Study)
(apixaban) and no oral anticoagulation in patient with sinus rhythm one year after catheter ablation of AF.
- 0 views
- 24 Jan, 2021
HElping Alleviate the Longer-term Consequences of COVID-19 (HEAL-COVID)
quality of life associated with COVID-19. The first two treatment arms are Apixaban and Atorvastatin, with further treatment arms to be added at the direction of the UK COVID-19 Therapeutic
- 0 views
- 02 Aug, 2021
- 1 location
Apixaban for Intrahepatic Non Cirrhotic Portal Hypertension (APIS)
and TIPSS (transjugular intrahepatic portosystemic shunt) or liver transplantation for severe cases. The investigators hypothesize that anticoagulation using Apixaban in patients with INCPH
- 3 views
- 05 Apr, 2022
- 1 location
DOT HeartMate 3 Study
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
- 0 views
- 21 Apr, 2022
- 1 location
API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT)
The main objective is to determine whether a low-dose regimen of apixaban (2.5 mg bid) is non inferior to a full-dose regimen of apixaban (5 mg bid) for the prevention of recurrent venous
- 34 views
- 04 Oct, 2022
- 71 locations
COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation
regular blood tests and do not interact with foods. Two of the new blood thinners are called rivaroxaban and apixaban. Like warfarin, they can be taken by mouth, and studies have shown them to be as
- 4 views
- 11 Nov, 2021
- 1 location
A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE (ASTER)
This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and
- 0 views
- 04 Oct, 2022
- 12 locations
Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism (COBRRA)
Apixaban and rivaroxaban have been compared to standard therapy for treatment of acute symptomatic venous thromboembolism (VTE) in randomized controlled trials (RCTs), and are both approved by
- 295 views
- 31 Jan, 2022
- 17 locations
Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism (HI-PRO)
Design: U.S.-based, single-center, randomized placebo-controlled trial. Brief Treatment Description: Low-intensity apixaban (2.5mg twice daily) for extended-duration secondary prevention
- 0 views
- 04 Oct, 2022
- 1 location